NL Harris SH Swerdlow G Frizzera DM Knowles 2001 Post-transplant lymphoproliferative disorders ES Jaffe NL Harris H Stein JW Vardiman Tumours of Haematopoietic and Lymphoid Tissues; Pathology and Genetics IARC Press Lyon 264 269
Posttransplant lymphoproliferative disorders in renal allograft recipients: Report of 53 cases of a French multicenter study
suppl 3
S Caillard V Lachat B Moulin 2000 Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study PTLD French Working Group. Transpl Int 13 suppl 3 88 93
Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
for the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).
VR Dharnidharka EK Sullivan DM Stablein AH Tejani WE Harmon for the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). 2001 Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Transplantation 71 1065 1068
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): Prevention and treatment
EBPG Expert Group on Renal Transplantation.
EBPG Expert Group on Renal Transplantation. 2002 European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV. 6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment Nephrol Dial Transpl 17 35 36
CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab
JJ Ifthikharuddin LA Mieles JD Rosenblatt CK Ryan DM Sahasrabudhe 2000 CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab Am J Hematol 65 171 173
Abdominal-pelvic lymphoproliferative disease after lung transplantation: Presentation and outcome
RR Hachem MM Chakinala RD Yusen JP Lynch AA Aloush GA Patterson EP Trulock 2004 Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome Transplantation 77 431 437
Latent membrane protein 1, tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF-2, TRAF-3, and nuclear factor kappa B expression in posttransplantation lymphoproliferative disorders
P Ramalingam WS Chu R Tubbs L Rybicki J Pettay ED Hsi 2003 Latent membrane protein 1, tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF-2, TRAF-3, and nuclear factor kappa B expression in posttransplantation lymphoproliferative disorders Arch Pathol Lab Med 127 1335 1339
Immunodeficiency-related lymphoproliferative disorders: Prospective data from the Registry
CR Pinkerton I Hann CL Weston T Mapp A Wotherspoon R Hobson DA Kelly D Vergani D Hadzic L Rees M Burke J Alero Thomas 2002 Immunodeficiency-related lymphoproliferative disorders: prospective data from the Registry Br J Haematol 118 456 461
Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: Implications for immune-based therapy
ML Gulley LJ Swinnen KT Plaisance Jr C Schnell TM Grogan BG Schneider 2003 Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy Transplantation 76 959 964